Neuroprotection Research for Parkinson's Disease

Neuroprotection — the ability to slow, stop, or prevent the progressive loss of dopamine neurons — remains the single most important unmet need in Parkinson's disease treatment. Every currently available therapy manages symptoms without addressing the underlying neurodegeneration. As of early 2026, no proven neuroprotective therapy exists, and a pivotal GLP-1 agonist trial that many had hoped would change this has failed to show significant benefit. But the search continues with more sophisticated strategies and better tools than ever before.

Why Neuroprotection Is So Difficult

Understanding why previous neuroprotection trials have failed is essential for interpreting current research. The challenges are not merely technical — they are fundamental to the biology of the disease:

• The disease starts decades before diagnosis. By the time motor symptoms appear and Parkinson's is diagnosed, an estimated 50-70% of dopamine neurons have already been lost. Intervening at this point may be too late to dramatically alter the disease course. Biomarkers that enable earlier diagnosis — such as the alpha-synuclein seed amplification assay (SAA) and blood-based tests under development — could eventually allow intervention when more neurons remain salvageable.
• Multiple mechanisms of cell death. Dopamine neurons do not die from a single cause. Alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, neuroinflammation, lysosomal impairment, and disrupted cellular waste disposal all contribute. A drug targeting one mechanism may fail if others continue unchecked.
• Measuring neuroprotection is methodologically challenging. How do you prove that a drug slows progression rather than simply improving symptoms? Symptomatic benefit can mask or mimic neuroprotection. Innovative trial designs — such as delayed-start designs (where one group begins treatment later and is compared to the group that started earlier) and washout designs (where the drug is stopped to see if benefits persist) — attempt to separate these effects, but they are complex, lengthy, and expensive.
• Patient heterogeneity. Parkinson's disease almost certainly comprises multiple subtypes with different underlying mechanisms, rates of progression, and genetic contributions. A treatment that works in one subtype may fail in another, diluting the overall effect in a mixed trial population. The field is increasingly recognizing that precision medicine — matching specific treatments to specific subtypes — may be necessary.

GLP-1 Receptor Agonists: A Cautionary Tale of Evolving Evidence

GLP-1 (glucagon-like peptide-1) receptor agonists, originally developed for type 2 diabetes, attracted significant attention as potential neuroprotective agents for Parkinson's disease. Preclinical studies showed that these drugs reduced neuroinflammation, improved mitochondrial function, and promoted neuronal survival. But the clinical trial data have delivered a sobering reality check.

Exenatide: Phase 3 Failure (Lancet, 2025)

The most definitive test of GLP-1 agonists in Parkinson's to date was the Phase 3 trial of exenatide, published in The Lancet in 2025. This trial failed to show significant efficacy.

This result was particularly disappointing because an earlier Phase 2 trial published in The Lancet in 2017 had generated significant optimism. In that smaller study, patients receiving exenatide showed improvements in motor function that persisted even after a 12-week washout period (when the drug was stopped), which was interpreted as possible evidence of disease modification rather than purely symptomatic benefit. The Phase 3 trial, designed to definitively confirm or refute this signal, did not replicate the finding.

Lixisenatide: Modest Signal, Significant Side Effects (NEJM, 2024)

The LIXIPARK trial, published in the New England Journal of Medicine in 2024, tested lixisenatide (another GLP-1 agonist) in 156 people with early Parkinson's disease. Over 12 months, patients receiving lixisenatide showed less motor decline on the MDS-UPDRS Part III scale compared to placebo — the most positive result among GLP-1 agonists tested in Parkinson's.

However, the result requires careful interpretation:

• The effect size was modest.
• Gastrointestinal side effects were substantial: 46% of participants experienced nausea and 13% experienced vomiting.
• The trial lasted only 12 months — too short to determine whether the effect represents true disease modification or a sustained symptomatic benefit.
• The study was Phase 2 with a relatively small number of participants and was not powered to definitively prove neuroprotection.

Other GLP-1 Trials

Trials of liraglutide and NLY01 (a pegylated form of exenatide) have produced inconclusive results. In total, six published trials of four GLP-1 family members have been completed, with only lixisenatide showing superiority to placebo.

Current Status and Ongoing Research

The Parkinson's Foundation explicitly states that GLP-1 drugs like Ozempic (semaglutide) are not proven treatments for Parkinson's disease and should not be used outside research settings. Despite widespread media coverage suggesting a connection between diabetes drugs and Parkinson's protection, the clinical evidence does not support this claim.

The MOST-ABLE trial of semaglutide (the active ingredient in Ozempic and Wegovy) in Parkinson's disease was completing enrollment as of March 2026. This trial will provide additional data on whether any GLP-1 agonist has clinically meaningful neuroprotective effects. However, given the Phase 3 exenatide failure, expectations should be tempered.

Alpha-Synuclein-Targeted Therapies

Targeting the toxic accumulation of misfolded alpha-synuclein — the protein that forms Lewy bodies and is believed to drive neuronal death — is both a neuroprotective strategy and a disease-modification approach. If alpha-synuclein aggregation is what kills neurons, preventing or clearing those aggregates could protect remaining cells.

Prasinezumab: The Most Advanced Program

Prasinezumab (Roche/Prothena), an anti-alpha-synuclein monoclonal antibody, entered a 900-patient Phase 3 trial in November 2025 — the largest test of this approach to date. The Phase 2b PADOVA trial narrowly missed its primary endpoint (hazard ratio 0.84, p=0.0657) but showed a signal in levodopa-treated patients (HR=0.79, p=0.04). Whether this signal represents genuine disease modification will be determined by the Phase 3 trial, expected to report results around 2029.

It is important to note that another alpha-synuclein antibody, cinpanemab (Biogen), showed no benefit in a Phase 2 trial and was discontinued (NEJM, 2022). Targeting alpha-synuclein after symptoms appear may be insufficient, may require the right dose and patient population, or may need to be combined with other approaches. The science is genuinely uncertain.

Antisense Oligonucleotides (ASOs)

Rather than clearing alpha-synuclein after it has aggregated, antisense oligonucleotides aim to reduce production of the protein at the genetic level by targeting its messenger RNA. Preclinical evidence shows prevention and reversal of alpha-synuclein pathology. This approach is in early human testing, with initial safety and pharmacodynamic data emerging.

Anti-Inflammatory and Genetic Approaches

LRRK2 Inhibitors

Mutations in the LRRK2 gene are the most common genetic cause of familial Parkinson's (found in 1-2% of sporadic cases). LRRK2 is also involved in immune cell function, and excessive LRRK2 kinase activity drives neuroinflammation. Importantly, LRRK2 inhibitors may also normalize lysosomal dysfunction caused by GBA1 mutations, making them potentially relevant beyond just LRRK2 mutation carriers.

BIIB122 (Biogen/Denali) was the most advanced LRRK2 inhibitor, but its Phase 2b LUMA trial did not slow disease progression and the drug was discontinued for idiopathic Parkinson's in May 2026. A separate Phase 2a study (BEACON) in people who carry a LRRK2 variant is ongoing, with results expected in the first half of 2027.

GCase Activators (GBA1-Targeted)

GBA1 mutations, found in 10-15% of sporadic Parkinson's cases, impair the enzyme glucocerebrosidase (GCase), compromising cellular waste disposal and alpha-synuclein clearance. Pharmacological agents that enhance GCase activity are being tested:

• BIA 28-6156: Tested in the ACTIVATE trial for GBA1-associated Parkinson's, but it failed its Phase 2b endpoints and was discontinued in June 2026.
• GT-02287: A GCase activator in Phase 1b extension testing, with data expected September 2026.

NLRP3 Inflammasome Inhibitors

The NLRP3 inflammasome is a key driver of neuroinflammation, and its activation has been linked to Parkinson's disease progression. Dapansutrile, an NLRP3 inflammasome inhibitor, entered Phase 2 testing (DAPA-PD trial) in early 2026. This represents a new class of anti-inflammatory approach distinct from general immunosuppression.

Other Anti-Inflammatory Strategies

• Azathioprine (AZA-PD trial): An established immunosuppressant being tested to determine whether suppressing peripheral immune activation can slow Parkinson's progression.
• Sargramostim (GM-CSF): An immune-modulating drug that showed potential neuroprotective effects in a small trial and is being studied further.

Mitochondrial Protection

Mitochondria — the energy-producing structures within cells — have been implicated in Parkinson's since the discovery that the toxin MPTP, which selectively destroys dopamine neurons, works by poisoning mitochondria. Mitochondrial dysfunction is consistently found in Parkinson's, and genetic forms of the disease (PINK1, Parkin mutations) directly affect mitochondrial quality control.

• Coenzyme Q10: Once a leading candidate, a large NIH-funded trial (QE3) showed no benefit, effectively ending this line of investigation as a standalone neuroprotective approach.
• Ursodeoxycholic acid (UDCA): This bile acid, FDA-approved for liver disease, has shown mitochondrial protective effects in preclinical Parkinson's models and is being tested in the UP clinical trial.
• PINK1/Parkin pathway activators: Drugs that enhance the mitochondrial quality control pathway are in preclinical development. Since PINK1 and Parkin mutations cause early-onset Parkinson's by impairing this pathway, enhancing it could benefit both genetic and non-genetic forms of the disease.

Iron Chelation

Iron accumulates in the substantia nigra in Parkinson's disease and may contribute to oxidative stress and neuronal death. Deferiprone, an iron chelator, has been tested in clinical trials with mixed results — some showing modest motor function benefits, others showing no difference from placebo. The inconsistency may reflect patient heterogeneity: iron chelation could benefit a subgroup of patients with particularly high iron accumulation but not the broader Parkinson's population.

Exercise as Neuroprotection

While not a drug, exercise is currently the most evidence-supported neuroprotective intervention available for people with Parkinson's disease. The evidence base is substantial and growing:

• Cochrane Review (2023): A systematic review of 156 randomized controlled trials involving 7,939 participants found small-to-large beneficial effects of multiple exercise types on motor function and quality of life.
• Network meta-analysis (Frontiers in Neurology, 2025): Analyzed 55 RCTs and found that different exercise types have distinct benefits — exoskeletal training for balance, resistance training for quality of life, mind-body exercise (tai chi, yoga) for cognitive function, and aerobic exercise for walking velocity at an optimal dose of approximately 1,400 METs-minutes per week.
• SPARX trial: Demonstrated that high-intensity treadmill exercise resulted in no worsening of motor symptoms over six months in newly diagnosed patients — a finding consistent with a neuroprotective effect, though the trial was not designed to prove neuroprotection definitively.
• Animal model evidence: Consistent data showing that exercise promotes neuroplasticity, reduces neuroinflammation, increases brain-derived neurotrophic factor (BDNF), and may protect dopamine neurons from further damage. Exercise has also been shown to improve mitochondrial health, one of the key cellular pathways disrupted in Parkinson's.

Human studies cannot ethically prove neuroprotection through exercise (this would require randomizing people to no exercise), but large observational studies consistently show that people who exercise regularly have slower disease progression, better motor and cognitive function, and better quality of life. The evidence supports the recommendation that all people with Parkinson's engage in regular, sustained, moderate-to-vigorous exercise — not only for symptomatic benefit but for its potential to slow the disease.

Platform Trials: A New Approach to Testing

Recognizing that testing one drug at a time in separate, costly trials is too slow, the field is moving toward platform trial designs. The most notable example is the SLEIPNIR platform (Cure Parkinson's), which began recruitment in 2026 and is designed to test multiple disease-modifying candidates simultaneously within a shared infrastructure. This approach reduces cost, accelerates timelines, allows direct comparison between treatments, and can adaptively drop ineffective arms while adding new ones.

The Path Forward

The neuroprotection field is evolving in several important directions:

• Earlier intervention. Biomarkers that identify Parkinson's before motor symptoms — including the alpha-synuclein SAA and prodromal screening based on REM sleep behavior disorder and anosmia — are enabling trials to target the pre-clinical stage, when neuroprotection may be most effective.
• Precision medicine. Treating Parkinson's subtypes with targeted therapies (LRRK2 inhibitors for LRRK2 carriers, GCase activators for GBA1 carriers) rather than a one-size-fits-all approach. This is the most likely path to the first proven disease-modifying therapy.
• Combination therapy. Attacking multiple disease mechanisms simultaneously — for example, combining an anti-inflammatory agent with an alpha-synuclein-lowering therapy — may be more effective than single-target approaches.
• Better trial designs. Adaptive platform trials (SLEIPNIR), biomarker-enriched cohorts, digital monitoring with wearable devices, and innovative statistical approaches are making trials more efficient and more likely to detect real effects.

No neuroprotective therapy for Parkinson's has yet been proven, and the GLP-1 agonist experience is a reminder that even well-supported biological rationales and promising Phase 2 results do not guarantee Phase 3 success. But the scientific tools and understanding now available — precision genetic targeting, biomarker-based patient selection, and multi-mechanism combination approaches — are more powerful than at any point in the history of the disease.

In the meantime, the best available evidence supports exercising vigorously and consistently, optimizing symptom management with your neurologist, and considering clinical trial participation. These are active choices that improve your present quality of life and may contribute to the scientific breakthroughs that will improve the future for everyone with Parkinson's disease.

For research updates and clinical trial matching, visit the Michael J. Fox Foundation or the Parkinson's Foundation (Helpline: 1-800-4PD-INFO / 1-800-473-4636).